Search results
Results From The WOW.Com Content Network
Means dedicated her practice to functional medicine, which focuses on the root causes of disease. In 2019, she co-founded the digital health company Levels Health, which produces a continuous glucose monitor. [4] [5] Casey and Calley Means co-authored the 2024 book Good Energy: The Surprising Connection Between Metabolism and Limitless Health. [6]
Dr. Casey Means left healthcare frustrated by doctors playing middlemen with people's health. She's now shaping RFK Jr's plan to "Make America Healthy Again."
Ferritin is a biomarker that reflects iron stores in the body. Testing ferritin levels on a blood panel is one of the diagnostic thresholds of diagnosing iron deficiency, says von Drygalski. The ...
A biomarker can be a traceable substance that is introduced into an organism as a means to examine organ function or other aspects of health. [7] It can also be a substance whose detection indicates a particular disease state, for example, the presence of an antibody may indicate an infection. [7]
Omentin is an anti-inflammatory adipokine produced preferentially by visceral adipose tissue. Plasma omentin-1 levels are significantly decreased in patients with obesity, insulin resistance and diabetes that contribute to the major components of the metabolic syndrome.
In medicine, a biomarker is a measurable indicator of the severity or presence of some disease state. It may be defined as a "cellular, biochemical or molecular alteration in cells, tissues or fluids that can be measured and evaluated to indicate normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention."
Pages in category "Biomarkers" The following 82 pages are in this category, out of 82 total. ... 5-Methylcytosine; 7-Methylguanosine; 3-Methylhistidine; MiR-122;
Biomarker discovery is a medical term describing the process by which biomarkers are discovered. Many commonly used blood tests in medicine are biomarkers. There is interest in biomarker discovery on the part of the pharmaceutical industry; blood-test or other biomarkers could serve as intermediate markers of disease in clinical trials, and as possible drug targets.